

TECHNICAL SHEET IDYLLA™ BRAF MUTATION ASSAY



The **Idylla™ BRAF Mutation Assay**, performed on the Biocartis Idylla™ System, is a molecular assay for the qualitative detection of **V600E/E2/D** and **V600K/R/M** mutations in **codon 600** of the BRAF gene.

The **Idylla™ BRAF Mutation Assay**, from **sample-to-result**, starts with formalin-fixed paraffin-embedded (FFPE) tissue to liberate DNA for subsequent real-time PCR amplification and detection.

FEATURES

BRAF mutation detection

BRAF V600E	(c.1799T>A)
BRAF V600E2	(c.1799_1800delinsAA)
BRAF V600D	(c.1799_1800delinsAT; c.1799_1800delinsAC)

Codon 600

BRAF V600K	(c.1798_1799delinsAA)
BRAF V600R	(c.1798_1799delinsAG)
BRAF V600M	(c.1798G>A)

BRAF Wild Type	(c.1799T)
----------------	-----------

RNaseP (acting as Sample Processing Control)

Specimen requirements

Sample Type	FFPE tissue sections (5 to 10 µm)
-------------	-----------------------------------

Neoplastic cells	≥50%, if less macrodissection is required
------------------	---

Tissue area	50-600 mm ² (5 µm)
	25-300 mm ² (10 µm)

Total turnaround time

Time	90 minutes
------	------------

Result Reporting

Report	Qualitative genotype call
--------	---------------------------



Biocartis trademark and logo are trademarks belonging to Biocartis and are used and registered in Europe. Idylla is a registered trademark in the United States (US) and other countries. Idylla trademark and logo are used trademarks belonging to Biocartis. Idylla™ platform is a CE-marked IVD in Europe. Idylla™ BRAF Mutation Assay is available for Research Use Only (RUO), not for use in diagnostic procedures.

[REF: ONCO_TS_BRAF_US_201812](#)